New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2014
07:55 EDTKYTHKythera price target raised to $55 from $50 at Leerink
Leeirnk raised its price target for Kythera shares to $55 after its survey indicated "significant demand" for the company's ATX-101, which aims to reduce submental fat. The firm keeps an Outperform rating on the stock.
News For KYTH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 5, 2015
08:04 EDTKYTHAllergan and KYTHERA announce pending transaction to be all-cash consideration
Subscribe for More Information
July 27, 2015
16:46 EDTKYTHAllergan, KYTHERA announce early termination of HSR waiting period
Subscribe for More Information
09:03 EDTKYTHKYTHERA announces Health Canada authorization of Belkyra
KYTHERA Biopharmaceuticals announced it has received authorization from Health Canada to market Belkyra "for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.” Belkyra is a non-surgical treatment for improving the appearance and profile of submental fullness—more commonly known as “double chin,” a facial aesthetic condition that affects both women and men. Belkyra was recently launched in the U.S. under the brand name Kybella.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use